In a strategic move reflecting its growth and expansion ambitions, Middle East Pharmaceutical Industries Company (Avalon Pharma), a leading pharmaceutical and cosmetics company in Saudi Arabia, announced that its board of directors has recommended a capital increase. According to an official statement published on the Saudi Stock Exchange (Tadawul), this recommendation aims to strengthen the company's capital base and support its ambitious future plans.
The recommendation includes a 75% capital increase for Avalon Pharma, raising it from SAR 200 million to SAR 350 million. This increase will be implemented through a bonus share issue to shareholders, at a rate of three new shares for every four shares held. This will increase the company's total number of shares from 200 million to 350 million. The company explained that this process will be funded by capitalizing SAR 150 million from retained earnings, reflecting its strong financial position and its ability to self-finance its growth. It should be noted that this recommendation remains subject to obtaining the necessary approvals from the relevant regulatory authorities and the approval of the company's Extraordinary General Assembly.
This move comes at a crucial stage of growth for Avalon Pharma, particularly following its successful listing on the Saudi Stock Exchange (Tadawul) in early 2024, which saw significant investor interest. This recommendation aligns with the strategic objectives of Saudi Vision 2030, which aims to localize vital industries, including pharmaceuticals, and enhance the Kingdom's drug security. By strengthening its capital base, Avalon Pharma is ideally positioned to benefit from government support for the sector, expand its production capacity, and develop new products to meet the growing needs of the local market.
The significance of this capital increase lies in enabling the company to accelerate the implementation of its expansion projects. The additional funds are expected to contribute to financing research and development, upgrading production lines, and potentially entering into strategic partnerships or acquisitions to enhance its product portfolio. Financially, this action strengthens the company's solvency and capital structure, thereby increasing investor and creditor confidence. For shareholders, the distribution of bonus shares signals management's confidence in the company's future performance and its ability to generate sustainable profits, while also contributing to increased stock liquidity in the market.
Looking ahead, this recommendation marks the beginning of a new phase of growth for Avalon Pharma. With a portfolio of over 60 well-known pharmaceutical and cosmetic brands, this capital boost will allow the company to expand its geographic reach both within the Kingdom and internationally, targeting new markets in the Middle East and North Africa region. This move will contribute to maximizing long-term shareholder returns and solidify Avalon Pharma’s position as a key player in the pharmaceutical industry, both locally and regionally.
